StreetInsider.com News Articles

Mirum Pharmaceuticals (MIRM) Reiterated at Market Outperform by Citizens

Fri, 17 Jul 2026 05:13:27 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $146.00 price target on Mirum Pharmaceuticals (NASDAQ: MIRM).

The analyst commented, "We reiterate our Market Outperform rating and $146 risk-adjusted, DCF-derived price target on Mirum Pharmaceuticals. For 2Q26, we model $167M in total revenues, which is slightly above consensus of $166M, with management guiding to 2026 total revenues of $660-$680M, which we think is attainable (Citizens estimate of $678M vs. consensus of $676M)."

For an analyst ratings summary and ratings history on Mirum Pharmaceuticals click here. For more ratings news on Mirum Pharmaceuticals click here.

Shares of Mirum Pharmaceuticals closed at

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 13 Jul 2026 16:01:00 -0400

FOSTER CITY, Calif.--(BUSINESS WIRE)-- Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM), a leading rare disease company, today announced that on July 10, 2026, the Compensation Committee of Mirum’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 6,300 shares of common stock and 9,300 restricted stock units (“RSUs”) to 6 new employees under Mirum’s 2020 Inducement Plan. The Compensation Committee of Mirum’s Board of Directors approved the awards as an inducement material to the new employees’ employment in accordance with Nasdaq Listing Rule 5635(c)(4).

Each stock option has an exercise price of $122.13 per share, which

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 13 Jul 2026 16:01:00 -0400

Each stock option has an exercise price of $122.13 per share, which

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 13 Jul 2026 16:01:00 -0400

Each stock option has an exercise price of $122.13 per share, which

Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 13 Jul 2026 16:01:00 -0400

Each stock option has an exercise price of $122.13 per share, which

Form 4 Mirum Pharmaceuticals, For: Jul 06 Filed by: Peetz Christopher

Wed, 08 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26748317.html

Form 4 Mirum Pharmaceuticals, For: Jul 06 Filed by: Peetz Christopher

Wed, 08 Jul 2026 17:13:00 -0400

si-local-file:///var/storage/secattach/20260708/26748317.html

Form 4 Mirum Pharmaceuticals, For: Jul 06 Filed by: BJERKHOLT ERIC

Wed, 08 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260708/26748280.html

Form 4 Mirum Pharmaceuticals, For: Jul 06 Filed by: BJERKHOLT ERIC

Wed, 08 Jul 2026 17:08:00 -0400

si-local-file:///var/storage/secattach/20260708/26748280.html

Mirum Pharmaceuticals (MIRM) PT Raised to $148 at RBC Capital

Tue, 07 Jul 2026 08:00:20 -0400

RBC Capital analyst Lisa Walter raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $148.00 (from $142.00) while maintaining a Outperform rating.

Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC

Mon, 06 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260706/26735553.html

Form 144 Mirum Pharmaceuticals, Filed by: BJERKHOLT ERIC

Mon, 06 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260706/26735553.html

Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher

Mon, 06 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260706/26735564.html

Form 144 Mirum Pharmaceuticals, Filed by: Peetz Christopher

Mon, 06 Jul 2026 16:10:00 -0400

si-local-file:///var/storage/secattach/20260706/26735564.html

Form 4 Mirum Pharmaceuticals, For: Jul 01 Filed by: Howe Jolanda

Thu, 02 Jul 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729840.html

Form 4 Mirum Pharmaceuticals, For: Jul 01 Filed by: Howe Jolanda

Thu, 02 Jul 2026 18:01:00 -0400

si-local-file:///var/storage/secattach/20260702/26729840.html

Mirum Pharmaceuticals (MIRM) PT Raised to $125 at JPMorgan

Thu, 02 Jul 2026 07:24:43 -0400

JPMorgan analyst Jessica Fye raised the price target on Mirum Pharmaceuticals (NASDAQ: MIRM) to $125.00 (from $115.00) while maintaining a Overweight rating.

Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda

Wed, 01 Jul 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260701/26722175.html

Form 144 Mirum Pharmaceuticals, Filed by: Howe Jolanda

Wed, 01 Jul 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260701/26722175.html

Form 4 Mirum Pharmaceuticals, For: Jun 17 Filed by: Howe Jolanda

Thu, 18 Jun 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260618/26667549.html

Form 4 Mirum Pharmaceuticals, For: Jun 17 Filed by: Howe Jolanda

Thu, 18 Jun 2026 18:39:00 -0400

si-local-file:///var/storage/secattach/20260618/26667549.html

Form 8-K Mirum Pharmaceuticals, For: Jun 15

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665956.html

Form 8-K Mirum Pharmaceuticals, For: Jun 15

Thu, 18 Jun 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260618/26665956.html

Form 4 Mirum Pharmaceuticals, For: Jun 15 Filed by: Heron Patrick J

Wed, 17 Jun 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260617/26661541.html

Form 4 Mirum Pharmaceuticals, For: Jun 15 Filed by: Heron Patrick J

Wed, 17 Jun 2026 20:30:00 -0400

si-local-file:///var/storage/secattach/20260617/26661541.html